This advanced procedure helps stop the progression of keratoconus.
Advanced corneal collagen cross-linking uses ultraviolet (UV) light with vitamin B2 (riboflavin) eye drops to strengthen corneal tissue. The treatment can slow or halt the progression of keratoconus. Led by Newsom Eye founder, T. Hunter Newsom, MD, Newsom Eye is proud to offer this treatment option to patients with keratoconus, providing them with NEWsom EYES!
What is Keratoconus?
Keratoconus is an abnormality of the eye in which the normally round, dome-shaped cornea weakens and becomes progressively thinner and irregular in shape. The resulting cone-shaped cornea can cause high levels of astigmatism (irregular curvature) and nearsightedness. Keratoconus has been estimated to occur in one out of every 1,000 persons in the general population, and is generally first diagnosed in young people at puberty or in their late teens. Prior to collagen cross-linking, there was no way to stop the progression of this disease.
What Is Collagen Cross-Linking?
Corneal collagen cross-linking (CXL), a procedure first developed in Dresden, Germany, in the 1990’s, is a technique used to treat individuals with progressive keratoconus. This is the only procedure that can strengthen the cornea to slow or stop the progression of keratoconus. This minimally invasive treatment utilizes Vitamin B2 (riboflavin) and ultraviolet (UVA) light to increase the cornea’s collagen connections (cross-links), thus helping the cornea retain its firmness and shape. Collagen cross-linking is not a cure for keratoconus.